Consequently, Aldo‐mediated increases in vulnerable plaques may explain both the reduction in cardiovascular ischemic events in patients receiving MR antagonists and the increased incidence of myocardial infarction and death in patients with higher aldosterone levels or in the treatment arm of the torcetrapib trials. The gene discussed is NR3C2; the disease is myocardial infarction.